SCYNEXIS, Inc. (NASDAQ : SCYX) today announced that it has commenced an underwritten public offering of shares of its common stock and warrants. In addition, SCYNEXIS expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock and warrants being offered on the same terms and conditions. All of the shares of common stock and warrants in the offering will be sold by SCYNEXIS. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

SCYNEXIS, Inc. (NASDAQ: SCYX) today announced the pricing of its previously announced underwritten public offering of 38,888,889 shares of common stock and warrants to purchase up to 38,888,889 shares of common stock. Each share of common stock and warrant to purchase one share of common stock are being sold at a combined public offering price of $0.90 per share and accompanying warrant. The gross proceeds to SCYNEXIS from this offering are expected to be approximately $35 million, before deducting underwriting discounts and commissions and other estimated offering expenses, and excluding the exercise of any warrants. All of the shares of common stock and warrants are being offered by SCYNEXIS.

SCYNEXIS, Inc. (SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the sale of its 6.0% Senior Convertible Notes due 2026 (the "notes") for an aggregate principal amount of $10.0 million. The notes were sold in a private offering to Puissance Capital Management pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"). "The proceeds from this transaction strengthen our balance sheet as we continue to advance our late-stage programs evaluating oral ibrexafungerp in multiple indications, with anticipated top-line data for our VANISH-306 Phase 3 trial early this quarter and a potential NDA submission of ibrexafungerp for the treatment of vaginal yeast infections later this year,” said Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS.

As of late, it has definitely been a great time to be an investor in SCYNEXIS.

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced positive results from its second interim efficacy analysis of the ongoing Phase 3 open-label FURI study. The study is evaluating oral ibrexafungerp as a salvage treatment in patients with difficult-to-treat mucocutaneous and invasive fungal infections that are refractory to or intolerant of current standards of care, or require a non-azole oral step-down therapy for treatment of azole-resistant Candida species. Ibrexafungerp is the first representative of a novel antifungal family, the 'fungerps', being developed for oral and intravenous (IV) usage to treat multiple serious fungal infections, including ones that have shown resistance or have not responded to existing therapies.

In April, SCYNEXIS announced positive top-line results from the Phase 3 VANISH-306 study evaluating oral ibrexafungerp for the treatment of Vulvovaginal Candidiasis (VVC), more.

Anyone researching SCYNEXIS, Inc. (NASDAQ:SCYX) might want to consider the historical volatility of the share price...

Oral ibrexafungerp continues to advance in multiple indicationsNearing completion of Phase 3 VANISH program, evaluating oral ibrexafungerp for the treatment of Vulvovaginal.

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced positive top-line results for its Phase 3 VANISH-306 study investigating the safety and efficacy of oral ibrexafungerp, a novel broad-spectrum antifungal, as a treatment for women with vulvovaginal candidiasis (VVC), also known as vaginal yeast infection. With these results, ibrexafungerp has now achieved superiority over placebo with a high degree of statistical significance on key study endpoints required for regulatory approval of the VVC indication in both VANISH pivotal trials, clearing the way for the NDA submission for the treatment of VVC in the second half of 2020.

Oral ibrexafungerp continues to show potential to address a broad range of indications ranging from vaginal yeast infections to life-threatening refractory invasive fungal.

Candida auris is another growing and serious infectious global health threat that particularly impacts healthcare settings. JERSEY CITY, N.J., March 26, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Dr. Nkechi Azie, SCYNEXIS’s VP of Clinical Development will deliver a live presentation on the Candida auris treatment landscape at the 22nd Annual Superbugs and Superdrugs Conference 2020, taking place virtually on March 30th and 31st. The presentation will provide an overview of the growing threat of a new multidrug-resistant fungal species, Candida auris, and potential treatment options including the Company’s lead candidate, ibrexafungerp.

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS, will participate in a panel discussion on fungal pathogens and the emerging treatment landscape at Maxim Group’s Infectious Disease Virtual Conference on May 5, 2020. To register for the virtual conference, please click here: Infectious Disease Virtual Conference: The Renaissance of the Anti-infective Sector.

SCYNEXIS, Inc. (SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that data from a preclinical study of oral ibrexafungerp in combination with azoles against Aspergillus species isolated from lung transplant recipients were presented at the 9th Advances Against Aspergillosis and Mucormycosis conference on February 27-29, 2020.

One of the biggest stories of last week was how SCYNEXIS, Inc. (NASDAQ:SCYX) shares plunged 34% in the week since its...

Is SCYNEXIS Inc (NASDAQ:SCYX) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after adjusting […]

Investors who take an interest in SCYNEXIS, Inc. (NASDAQ:SCYX) should definitely note that the CEO, President...

The following are top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 9.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics ...

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced the appointment of accomplished business development executive Philippe Tinmouth to its Board of Directors. Mr. Tinmouth brings over 20 years of experience across multiple business development and alliance management roles, and is retiring as Vice President and Head of Business Development at Vertex Pharmaceuticals Incorporated, a role he has held since 2013.

SCYNEXIS, Inc. (SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it has entered into a Common Stock Purchase Agreement (“Purchase Agreement”) of up to $20 million with Aspire Capital Fund, LLC (“Aspire Capital”). Under the terms of the agreement, SCYNEXIS has the right to sell to Aspire Capital, from time to time and in its sole discretion, up to $20 million in shares of SCYNEXIS’s common stock over the next 30 months, subject to certain limits.

SCYNEXIS, Inc. (NASDAQ : SCYX) today announced the closing of its previously announced underwritten public offering of 38,888,889 shares of common stock and warrants to purchase up to 38,888,889 shares of common stock. Each share of common stock and warrant to purchase one share of common stock were sold at a combined public offering price of $0.90 per share and accompanying warrant. The total gross proceeds to SCYNEXIS from this offering were approximately $35 million, including the exercise of the underwriters' option to purchase additional warrants, before deducting underwriting discounts and commissions and other estimated offering expenses, and excluding the exercise of any warrants. All of the shares of common stock and warrants were offered by SCYNEXIS.